Results 141 to 150 of about 87,402 (312)

Defining AV2‐1 as a novel pharmacological probe to target human and rodent TRPV2

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Transient receptor potential vanilloid 2 (TRPV2) is a non‐selective cation channel implicated in immune cell functions. However, progress in understanding TRPV2 has been limited by a lack of potent and selective pharmacological tools, particularly those targeting the human variant. We aimed to identify and characterise a
Andrea Leipe, Julia A. Rocereta, Ruth A. Pumroy, Andreas Leffler, Michael Schaefer, Vera Moiseenkova‐Bell, Kerstin Hill   +6 more
wiley   +1 more source

Tenosynovial Giant Cell Tumors in the Hand and Foot. [PDF]

Cureus
Stefanou N, Varitimidis S, Samaila EM, Koutis A, Karachalios T, Dailiana Z.   +5 more
europepmc   +1 more source

Clinical retrospective analysis with a predictive model for diffused-tenosynovial giant cell tumors of the temporomandibular joint. [PDF]

BMC Cancer, 2023
Liu Y, Huang Y, Zhu D, Li J, Zhao T, He Y, Xia R, Zhong L.   +7 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Tenosynovial Giant Cell Tumors: A Musculoskeletal Case Series. [PDF]

Cureus
Yip FC, Wong YK, Chong WH, Li OC, Kwok KY.   +4 more
europepmc   +1 more source

Expanding the molecular spectrum of tenosynovial giant cell tumors. [PDF]

Front Oncol, 2022
Gauduchon T, Vanacker H, Pissaloux D, Cassier P, Dufresne A, Karanian M, Meurgey A, Bouhamama A, Gouin F, Ray-Coquard I, Blay JY, Tirode F, Brahmi M.   +12 more
europepmc   +1 more source

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study

Cancer Science, EarlyView.
In patients with mCSPC treated with apalutamide plus ADT, baseline ctDNA predicted earlier progression to CRPC and worse overall survival. Exploratory genome‐wide analysis identified 12 SNPs associated with apalutamide‐related skin rash. ABSTRACT Despite promising evidence of the efficacy of the androgen deprivation therapy (ADT) plus apalutamide in ...
Masaki Shiota, Taku Naiki, Koji Hatano, Akira Yokomizo, Hiroaki Tsuchiya, Yoko Takahashi, Taku Nakayama, Masaki Yoshida, Hirotsugu Uemura   +8 more
wiley   +1 more source

Optimizing Functional Recovery in Multi-Site Giant Cell Tumors. [PDF]

J Orthop Case Rep
Dubey V, Prajapati M, Tolani M, Sharma S.   +3 more
europepmc   +1 more source

T2-star (T2*)-weighted magnetic resonance imaging of tenosynovial giant cell tumors. [PDF]

Eur J Radiol Open, 2023
Sakamoto A, Noguchi T, Matsuda S.
europepmc   +1 more source

CLINICAL AND MORPHOLOGICAL CORRELATIONS AND HISTOPATHOLOGY OF JOINT DAMAGE IN PATIENTS WITH DIFFUSE-TYPE TENOSYNOVIAL GIANT CELL TUMOR

, 2019
Olena O. Dyadyk, Anastasiia Hryhorovska
openalex   +1 more source